Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06292078 · ClinicalTrials.gov registry record · NA

Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)

A NA study of Middle Schools and School Exclusion, sponsored by University of Oregon.

Recruiting
Registry status
NA
Development phase
5,076
Enrollment target
3
Study locations

NCT06292078 is a NA study of Middle Schools and School Exclusion that is actively recruiting participants, run by University of Oregon. The registered enrollment target is 5,076 participants. The trial reports 3 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06292078, a NA study of Middle Schools and School Exclusion, is actively recruiting participants, sponsored by University of Oregon.

RECRUITING
Registry status
NA
Development phase
5,076 participants
Enrollment target
3
Study locations

Study Summary

This project will test the effectiveness of the Inclusive Skill-building Learning Approach (ISLA) in reducing the use of exclusionary discipline, improving teacher practice and student outcomes, and decreasing substance misuse using a randomized controlled trial in 60 middle schools across six states.

Interventions

  • BEHAVIORAL Instructional Skill-Building Learning Approach (ISLA)

Study Locations (3)

California

  • Soquel Union Elementary School District - Capitola
  • Riverbend School District - Yuba City

Oregon

  • Salem-Keizer School District - Salem

Trial Details

FieldValue
Enrollment Target 5,076 participants
Start Date 2024-04-15
Est. Completion 2027-10-01
Phase NA

Sponsor

University of Oregon

63 total trials

What the Registry Record Tells You About NCT06292078

The ClinicalTrials.gov registry entry for NCT06292078 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 5,076 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oregon, which has 63 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Middle Schools appearing as the primary indexed condition, and to 1 intervention - of which Instructional Skill-Building Learning Approach (ISLA) is the first listed.

NCT06292078 reports 3 study locations spanning 2 distinct geographic areas - top geographies include California, Oregon.

Frequently Asked Questions

What is clinical trial NCT06292078 about?

NCT06292078 is a clinical study titled "Preventing School Exclusion and Opioid Misuse: Effectiveness of the Inclusive Skill-building Learning Approach (ISLA)". This project will test the effectiveness of the Inclusive Skill-building Learning Approach (ISLA) in reducing the use of exclusionary discipline, improving teacher practice and student outcomes, and decreasing substance misuse using a randomized controlled trial in 60 middle schools across six state...

What is the current status of trial NCT06292078?

This trial is currently recruiting. It is a NA study. The enrollment target is 5,076 participants. The study started on 2024-04-15. Estimated completion is 2027-10-01.

What conditions does trial NCT06292078 study?

This clinical trial studies the following conditions: Middle Schools, School Exclusion, School Community, Teaching Practices, Opioid and Other Substance Misuse.

What interventions are being tested in trial NCT06292078?

The interventions under investigation include: Instructional Skill-Building Learning Approach (ISLA) (BEHAVIORAL).

Who is sponsoring clinical trial NCT06292078?

This trial is sponsored by University of Oregon, which has 63 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06292078 being conducted?

This trial has 3 study locations across California, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.